Ophthalmology Times reframes myopia as disease

Myopia sounds simple. You can’t see far away, so you get glasses or contacts, end of story. But that old framing misses the part that actually worries eye doctors — the eye itself can keep elongating, and that structural change raises the risk of damage later on. That is the shift Ophthalmology Times Europe pushed in a June 25, 2025 explainer by Gregory Ostrow and Laura Kirkeby: stop treating myopia as a benign refractive inconvenience and start treating progressive myopia as disease with consequences. ### Why are people suddenly talking about myopia this way? Because the numbers stopped looking small. The Ophthalmology Times Europe piece pulled together a now-familiar but still jarring forecast: global myopia prevalence climbed from 22.9% in 2000 to about 34% in 2020, and modelling still points to roughly half the world being myopic by 2050 — close to 5 billion people. High myopia, the more dangerous end of the spectrum, is projected to affect nearly 10% of the world by then. (europe.ophthalmologytimes.com) ### What makes high myopia different? Blur is the least interesting part. High myopia usually means a longer eye, and that stretch changes the retina, choroid, sclera, and optic nerve environment. The result is a much higher lifetime risk of retinal holes and detachments, myopic maculopathy, glaucoma, and earlier cataract. That is why clinicians care about axial elongation, not just the glasses prescription. (europe.ophthalmologytimes.com) ### So is myopia itself blinding? Usually, ordinary myopia is correctable. The danger is the tail risk as severity rises. Uncorrected refractive error remains a leading cause of distance vision impairment globally, but pathologic changes linked to high myopia can threaten sight even after the refractive error is fully corrected. Basically — glasses fix focus, not the stretched eye. (iovs.arvojournals.org) ### Why does this hit some places harder? Myopia is not evenly spread. Rates are highest in East Asia and in dense urban settings, and newer child and adolescent estimates show the burden still climbing. Ophthalmology Times Europe also stressed that preventable vision loss lands hardest where screening, follow-up, and treatment are patchy — which is the real public-health problem. (myopiainstitute.org) ### What changes in the clinic if you call it disease? The tone changes first. Instead of saying “your child just needs stronger glasses every year,” clinicians start talking about risk, progression, and surveillance. That means earlier identification of pre-myopia or fast progression, more counseling about outdoor time and near-work habits, and more willingness to use control strategies like atropine, specialty contact lenses, or spectacle designs meant to slow axial growth. (europe.ophthalmologytimes.com) ### Is this just semantics? Not really. Disease language changes what gets measured, monitored, and paid attention to. It nudges doctors to track axial length, not only refraction. It also helps explain to families why follow-up matters even when a child still sees well with correction. A stretched eye is a little like an overinflated balloon — the problem is not just the image on the surface, but the tension in the wall. That analogy is imperfect, but it gets at the structural risk. (pmc.ncbi.nlm.nih.gov) ### What is the bigger public-health angle? Eye-health groups already frame uncorrected refractive error and avoidable sight loss as massive, solvable burdens, especially in low- and middle-income countries. Recasting myopia as a progressive condition fits that agenda because it pushes action earlier — before a child becomes a highly myopic adult with irreversible retinal disease. (iovs.arvojournals.org) ### Bottom line The Ophthalmology Times Europe piece did not announce a new drug or guideline. The news was the framing itself. Myopia is common, but progressive myopia is not harmless — and the more medicine treats it like a disease process instead of a lens problem, the earlier the system can intervene. (visionatlas.iapb.org)